| Trial ID # | ISRCTN10356387; ICON8B |
| Phase | III |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Bevacizumab, Carboplatin, Paclitaxel |
| Eligible Participant | Newly diagnosed high-risk stage III/IV ovarian cancer |
| Patients Enrolled | 707; 53% stage IIIC, 40% stage IV, 91% HGSOC. 14% PDS, 84% IDS, 2% no surgery |
| Therapy Setting | First-line |
| Study Design | Double Blind, Randomized |
| Endpoints | PFS, OS, evaluated per RECIST |
| Biomarkers | High risk: stage IIIA1(ii), stage IIIA2 with positive retroperitoneal lymph nodes >1cm in diameter, stage IIIB or IIIC disease with >1cm residual disease following immediate primary surgery (IPS) or those receiving primary chemotherapy with or without delayed primary surgery (DPS), and all stage IV disease |
| Efficacy | Standard of Care (SoC): CarboPt AUC5 or AUC6+Pac 175mg/m2 every 3 weeks+Bev SoC+Bev (n=292) vs CarboPt q3w+Pac qw+Bev (n=286): PFS: 16.7 vs 22.2 months, HR: 0.75 (0.62-0.90, p=0.002) |
| Clinically Significant Adverse Events | SoC+Bev vs CarboPt q3w+Pac qw+Bev: |
| Conclusion | In primary treatment of high-risk stage IIIC/IV ovarian cancer, bevacizumab with weekly taxol and carboplatin improves PFS and OS compared to bevacizumab with standard three weekly chemotherapy |
| Reference | Clamp A et al. ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis. ESGO (2023) abstract 159 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.